BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 30314508)

  • 1. "Yellow-dragon Wonderful-seed Formula" for hyperuricemia in gout patients with dampness-heat pouring downward pattern: a pilot randomized controlled trial.
    Yu XN; Wu HY; Deng YP; Zhuang GT; Tan BH; Huang YZ; Tang SY; Tu X; Jordan JB; Zhong S
    Trials; 2018 Oct; 19(1):551. PubMed ID: 30314508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
    Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
    Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):182-183. PubMed ID: 29125593
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood glucose fluctuations detected by continuous glucose monitoring system in gout patients with normal glucose tolerance and the effect of urate-lowering therapy.
    Mu Z; Wang J; Wang W; Lv W; Chen Y; Wang F; Zhao Y; Dong B; Wang Y; Wang Z
    Int J Rheum Dis; 2020 Aug; 23(9):1145-1151. PubMed ID: 32483927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
    Yu KH; Chen DY; Chen JH; Chen SY; Chen SM; Cheng TT; Hsieh SC; Hsieh TY; Hsu PF; Kuo CF; Kuo MC; Lam HC; Lee IT; Liang TH; Lin HY; Lin SC; Tsai WP; Tsay GJ; Wei JC; Yang CH; Tsai WC
    Int J Rheum Dis; 2018 Apr; 21(4):772-787. PubMed ID: 29363262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
    Castrejon I; Toledano E; Rosario MP; Loza E; PĂ©rez-Ruiz F; Carmona L
    Rheumatol Int; 2015 Jul; 35(7):1127-37. PubMed ID: 25519877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
    Hosoya T; Sasaki T; Ohashi T
    Clin Rheumatol; 2017 Mar; 36(3):649-656. PubMed ID: 27832384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
    Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
    Torres RJ; Puig JG
    Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice.
    Liang G; Nie Y; Chang Y; Zeng S; Liang C; Zheng X; Xiao D; Zhan S; Zheng Q
    Phytomedicine; 2019 Jun; 59():152772. PubMed ID: 31005813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacist-managed titration of urate-lowering therapy to streamline gout management.
    Huang IJ; Liew JW; Morcos MB; Zuo S; Crawford C; Bays AM
    Rheumatol Int; 2019 Sep; 39(9):1637-1641. PubMed ID: 31147732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
    Liu C; Zhao Q; Zhen Y; Gao Y; Tian L; Wang L; Ji L; Liu G; Ji Z; Liu K
    Can J Cardiol; 2013 Sep; 29(9):1048-54. PubMed ID: 23395281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why better treatment of gout is needed.
    So AK
    Clin Exp Rheumatol; 2016; 34(4 Suppl 98):63-5. PubMed ID: 27586807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.